Peter Honig, DO
Adult Medicine · Philadelphia, PANPI 1194777466
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AstraZeneca at 50.5% of the total. Reporting peaked in 2023 at $34,656 and has fallen 59.7% since, to $13,954 in 2025. Among adult medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,136 payments — averaging $65.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- Pfizer$16K
- AbbVie$11K
- Johnson & Johnson$8K
- Novo Nordisk$4K
- Astrazeneca AB$3K
- plus $26K from 54 others
Across 2 payments — averaging $27,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$55K
What the payments were for
- Consulting fees$49,25235%
- Speaking & faculty fees$41,61530%
- Travel & lodging$11,4508%
- Food & beverage$37,23827%
- Education$2340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,789 in reported general payments places this provider in the 95th percentile of 52 adult medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 298 | $339,333 |
| FarxigaDapagliflozin Propanediol | 309 | $303,054 |
| EliquisApixaban | 576 | $294,154 |
| JardianceEmpagliflozin | 235 | $243,689 |
| VraylarCariprazine Hcl | 73 | $132,069 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $114,144 |
| XareltoRivaroxaban | 131 | $106,586 |
| MounjaroTirzepatide | 85 | $91,635 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $87,375 |
| JanuviaSitagliptin Phosphate | 93 | $79,626 |
| ProliaDenosumab | 44 | $76,168 |
| WegovySemaglutide | 54 | $70,397 |
| MyrbetriqMirabegron | 97 | $61,172 |
| RybelsusSemaglutide | 33 | $55,146 |
| LinzessLinaclotide | 65 | $52,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $4,036 | $464,875385 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $70,628 | $390,429405 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $1,397 | $295,940302 claims |
| PfizerEliquis | $15,581 | $294,154576 claims |
| AbbVieVraylar, Linzess, Creon, Savella | $11,363 | $241,021194 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,709 | $174,530277 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,355 | $131,651120 claims |
| Johnson & JohnsonXarelto | $8,323 | $106,586131 claims |
| MerckJanuvia | $605 | $79,62693 claims |
| AmgenProlia | $993 | $76,16844 claims |
| Astellas Pharma US IncMyrbetriq | $707 | $61,17297 claims |
| BayerKerendia | $1,419 | $37,85927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adult medicine providers in Pennsylvania.
Other adult medicine in Philadelphia
- Mark WatkinsPhiladelphia$54K
- Emily ScaruzziPhiladelphia$16K
- Harvey SpectorPhiladelphia$15K
- Paul lePhiladelphia$568
- Hadijatou JarraPhiladelphia$528
- Amy Orloff-FinePhiladelphia$469
- Agnes SimmonsPhiladelphia$439
- Hussein SafaPhiladelphia$389
- Nataliya NovykovaPhiladelphia$327
- Edward StraussPhiladelphia$277
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.